Erasca Reports Second Quarter 2024 Business Updates and Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/10/2026
- S&P 500 ends down as oil tops $100 per barrel
- Trump promises $5,000 payout to U.S. adults if Republicans win election
- Meta stock jumps 5% premarket: Analysts bullish on new Muse AI agent
- Rogers adds Sportsnet+ content to Xfinity TV packages for free
- AeroVironment (AVAV) Tops Q1 EPS by 29c, Offers Guidance
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
Erasca Inc (ERAS) PT Lowered to $3 at Goldman Sachs
August 13, 2024 1:52 PM EDTGoldman Sachs analyst Chris Shibutani lowered the price target on Erasca Inc (NASDAQ: ERAS) to $3.00 (from $4.00) while maintaining a Buy rating.
The analyst comments "Post the company's prior announcement in May of a strategic reset with subsequent financings, the company's 2Q24 operational and program updates (see... More
Erasca Inc (ERAS) PT Raised to $6 at H.C. Wainwright
August 13, 2024 6:11 AM EDTH.C. Wainwright analyst Andres Y. Maldonado raised the price target on Erasca Inc (NASDAQ: ERAS) to $6.00 (from $5.00) while maintaining a Buy rating.
The analyst comments "What to expect from the newly initiated SEACRAFT-2 study. Erasca recently announced the initiation of the global SEACRAFT-2 Phase 3 trial to evaluate the pan-RAF inhibitor naporafenib in combination with the MEK inhibitor trametinib for patients with NRAS-mutant melanoma. Our positive outlook on this program is... More
